Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	Cumulative Effect, Period of Adoption, Adjustment	Common Stock	Additional Paid-In Capital	Additional Paid-In Capital Cumulative Effect, Period of Adoption, Adjustment	Accumulated Deficit	Accumulated Deficit Cumulative Effect, Period of Adoption, Adjustment	Accumulated Other Comprehensive Income (Loss)	Non-controlling Interest -
Beginning balance (in shares) at Dec. 31, 2021			153,950,895
Beginning balance at Dec. 31, 2021	$ 670,881	$ (75,264)	$ 16	$ 1,691,206	$ (87,946)	$ (1,009,293)	$ 12,682	$ 172	$ (11,220)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock/At-the-market offering, net of offering costs (in shares)			50,620,577
Issuance of common stock/At-the-market offering, net of offering costs	292,155		$ 5	292,150
Exercise of common stock warrants (in shares)			540,541
Exercise of common stock warrants	10,249			10,249
Exercise of stock options (in shares)			616,304
Exercise of stock options	829			829
Delivery of common stock underlying restricted stock units (in shares)			1,956,231
Issuance of restricted stock (in shares)			2,000,000
Stock-based compensation	65,518			65,518
Foreign currency translation adjustment	(767)							(767)
Net loss attributable to non-controlling interest	(442)								(442)
Net loss attributable to common shareholders	(561,477)					(561,477)
Ending balance (in shares) at Dec. 31, 2022			209,684,548
Ending balance at Dec. 31, 2022	$ 401,682		$ 21	1,972,006		(1,558,088)		(595)	(11,662)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Accounting standards update	Accounting Standards Update 2020-06 [Member]
Issuance of common stock/At-the-market offering, net of offering costs (in shares)			81,694,729
Issuance of common stock/At-the-market offering, net of offering costs	$ 116,889		$ 8	116,881
Exercise of stock options (in shares)			339,842
Exercise of stock options	373			373
Delivery of common stock underlying restricted stock units (in shares)			3,729,918
Cancellation of escrow shares in connection with Edisn acquisition (in shares)			(12,595)
Cancellation of escrow shares in connection with Edisn acquisition	(344)			(344)
Issuance of restricted stock (in shares)			3,778,718
Issuance of restricted stock	4,199		$ 1	4,198
Stock-based compensation	44,620			44,620
Molotov non-controlling interest	(499)			(864)				374	(9)
Foreign currency translation adjustment	4,822							4,822
Net loss attributable to non-controlling interest	(463)								(463)
Net loss attributable to common shareholders	$ (287,454)					(287,454)
Ending balance (in shares) at Dec. 31, 2023	299,215,160		299,215,160
Ending balance at Dec. 31, 2023	$ 283,825		$ 30	2,136,870		(1,845,542)		4,218	(11,751)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock/At-the-market offering, net of offering costs (in shares)			33,218,851
Issuance of common stock/At-the-market offering, net of offering costs	43,310		$ 3	43,307
Exercise of common stock warrants (in shares)			4,042
Exercise of common stock warrants	$ 3			3
Exercise of stock options (in shares)	4,042
Delivery of common stock underlying restricted stock units (in shares)			6,706,801
Delivery of common stock underlying restricted stock units	$ 0		$ 1	(1)
Shares settled for taxes	(540)			(540)
Stock-based compensation	39,363			39,363
Foreign currency translation adjustment	(9,088)							(9,088)
Net loss attributable to non-controlling interest	(3,837)								(3,837)
Net loss attributable to common shareholders	$ (172,254)					(172,254)
Ending balance (in shares) at Dec. 31, 2024	339,144,854		339,144,854
Ending balance at Dec. 31, 2024	$ 180,782		$ 34	$ 2,219,002		$ (2,017,796)		$ (4,870)	$ (15,588)